What is the 13F Pro Quality Score for DNA?

13F Pro ranks Ginkgo Bioworks Holdings, Inc. (DNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DNA's current score at https://13fpro.ai/research/DNA (free sign-up required for the full ranking).

Which hedge funds own the most DNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DNA include BlackRock,, VIKING GLOBAL INVESTORS, BAILLIE GIFFORD & CO. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DNA as soon as new 13F filings post.

Where does 13F Pro source DNA data?

All Ginkgo Bioworks Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ginkgo Bioworks Holdings, Inc. files with the SEC under CIK 1830214. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DNA in?

Ginkgo Bioworks Holdings, Inc. (DNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DNA research updated on 13F Pro?

DNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ginkgo Bioworks Holdings, Inc.(DNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1830214 DNA stock profile & AI dashboard →

13F Pro Quality Score

11.7/100

Rank #2,791 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.8/100

Profitability

5.6/100

Balance Sheet

9.0/100

Earnings Quality

30.0/100

Free Cash Flow

6.4/100

Institutional Flow

42.8/100

Revenue Scale

21.6/100

Dilution Risk

4.8/100

DNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ginkgo Bioworks Holdings, Inc. (DNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNA at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,791 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (5.6) and revenue growth (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ginkgo Bioworks Holdings, Inc. reports quarterly revenue of $19.5M, net income of $-82.6M, free cash flow of $-48.6M. Top institutional holders of DNA by reported 13-F value include BlackRock,, VIKING GLOBAL INVESTORS, BAILLIE GIFFORD & CO, based on the most recent SEC filings. DNA trades on the NYSE exchange and files with the SEC under CIK 1830214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ginkgo Bioworks Holdings, Inc. directly from SEC EDGAR. Ginkgo Bioworks Holdings, Inc.'s 13F Pro composite quality score has ranged between 8 and 43 since 2021, currently 11.7 — a declining long-term trajectory across 53 quarterly and live scoring snapshots.

Revenue

Q1 2026

$19.5M

Net Income

Q1 2026

$-82.6M

Free Cash Flow

Q1 2026

$-48.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-25.1% YoY

$170.2MFY 2025

FY20 $76.7MFY21 $313.8MFY24 $227.0MFY25 $170.2M

Net Income

+42.8% YoY

$-313.0KFY 2025

FY20 $-126.6MFY21 $-1.8MFY24 $-547.0KFY25 $-313.0K

Operating Income

+43.7% YoY

$-315.3MFY 2025

FY20 $-137.0MFY21 $-1.83BFY24 $-559.8MFY25 $-315.3M

EPS (Diluted)

+46.5% YoY

$-5.64FY 2025

FY20 $-0.10FY21 $-1.39FY24 $-10.54FY25 $-5.64

Total Assets

-18.7% YoY

$1.12BFY 2025

FY20 $675.2MFY21 $2.07BFY24 $1.38BFY25 $1.12B

Op. Cash Flow

+46.5% YoY

$-171.1MFY 2025

FY20 $-135.8MFY21 $-253.8MFY24 $-319.6MFY25 $-171.1M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$170.2M -25.1%	$227.0M -27.7%	$313.8M +309.4%	$76.7M +41.5%	$54.2M	—
Net Income	$-313.0K +42.8%	$-547.0K +70.1%	$-1.8M +98.6%	$-126.6M -6.1%	$-119.3M	—
Operating Income	$-315.3M +43.7%	$-559.8M +69.4%	$-1.83B -1234.4%	$-137.0M -91.4%	$-71.6M	—
EPS (Diluted)	$-5.64 +46.5%	$-10.54 -658.3%	$-1.39 -1290.0%	$-0.10 +0.0%	$-0.10	—
Total Assets	$1.12B -18.7%	$1.38B -33.5%	$2.07B +206.7%	$675.2M -3.2%	$697.3M	—
Operating Cash Flow	$-171.1M +46.5%	$-319.6M -25.9%	$-253.8M -86.9%	$-135.8M -204.1%	$-44.7M	—

AI Insight: DNA Financial Trends

Ginkgo Bioworks revenue collapsed to $19M in Q1 2026 — the lowest in the visible dataset — while losses persist and equity erodes every quarter.

• Revenue fell sharply from $89M in Q3 2024 to $19M in Q1 2026, a deteriorating trajectory with no stabilization evident.

• Operating losses remain deep: op income ranged from $-55M to $-223M across all eight quarters, never approaching breakeven.

• Operating cash outflow improved modestly from $-104M in Q3 2024 to $-32M in Q3 2025, but reversed to $-47M in Q1 2026.

• Equity declined from $560M in Q3 2025 to $443M in Q1 2026, a $117M erosion in just two quarters.

⚠ Revenue at $19M in Q1 2026 is less than half Q2 2025's $50M — watch whether this accelerating top-line decline continues.

⚠ Equity shrinking $117M over two quarters with persistent cash burn raises near-term liquidity and runway concerns.

⚠ Debt data is absent across all periods — disclosure of leverage levels is needed to fully assess balance sheet risk.

AI Insight: DNA Ratio Trends

Ginkgo Bioworks remains deeply unprofitable with ROIC worsening to -64.4% in Q1 2026, and operating margins briefly collapsed to -184.1% in Q1 2025.

• Operating margin deteriorated sharply from -62.0% in Q3 2024 to -184.1% in Q1 2025 before partially recovering to -132.1% in Q2 2025.

• ROA has worsened from -15.2% in Q3 2024 to -32.0% in Q1 2026, signaling deepening asset-level losses.

• ROIC deteriorated from -55.6% in Q4 2025 to -64.4% in Q1 2026, continuing a deeply negative capital return profile.

⚠ ROE worsened from -63.5% in Q4 2025 to -74.5% in Q1 2026 — shareholder equity is eroding at an accelerating rate.

⚠ Data gaps across most quarters limit trend visibility; any sustained operating margin recovery above -62.0% would be a key inflection signal.

Get alerted when DNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ginkgo Bioworks Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DNA

BlackRock, Inc.
$22.3M3,642,347 sh
VIKING GLOBAL INVESTORS LP
$21.9M3,577,128 sh
BAILLIE GIFFORD & CO
$14.7M2,391,649 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.7M1,914,428 sh
Anchorage Capital Group, L.L.C.
$10.7M1,746,363 sh
Erste Asset Management GmbH
$10.7M1,947,728 sh
Legal & General Group Plc
$10.2M1,661,587 sh
STATE STREET CORP
$8.3M1,346,659 sh
FORBES J M & CO LLP
$6.3M1,028,391 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.2M1,009,362 sh

Fund	Value	Shares
BlackRock, Inc.	$22.3M	3,642,347
VIKING GLOBAL INVESTORS LP	$21.9M	3,577,128
BAILLIE GIFFORD & CO	$14.7M	2,391,649
VANGUARD CAPITAL MANAGEMENT LLC	$11.7M	1,914,428
Anchorage Capital Group, L.L.C.	$10.7M	1,746,363
Erste Asset Management GmbH	$10.7M	1,947,728
Legal & General Group Plc	$10.2M	1,661,587
STATE STREET CORP	$8.3M	1,346,659
FORBES J M & CO LLP	$6.3M	1,028,391
GEODE CAPITAL MANAGEMENT, LLC	$6.2M	1,009,362

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DNA on your watchlist

Track score changes the day Ginkgo Bioworks Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DNA a good stock to buy?

13F Pro's AI-powered analysis of Ginkgo Bioworks Holdings, Inc. (DNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNA are available on the DNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ginkgo Bioworks Holdings, Inc.'s investment landscape.